Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis

Clinical Therapeutics

Volumn 35, Issue 10, 2013, Pages 1490-1500.e7

  Malloy, Rhynn J ^a   Kanaan, Abir O ^a   Silva, Matthew A ^a   Donovan, Jennifer L ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Antiplatelet; Aspirin; Bleeding; Dipyridamole; Mixed treatment comparison; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; SARPOGRELATE; TERUTROBAN; TICLOPIDINE; TRIFLUSAL;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INTRAOCULAR HEMORRHAGE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; SECONDARY PREVENTION; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK;

ANTIPLATELET; ASPIRIN; BLEEDING; DIPYRIDAMOLE; MIXED TREATMENT COMPARISON; STROKE PREVENTION;

AGED; ASPIRIN; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SECONDARY PREVENTION; STROKE; TICLOPIDINE;

EID: 84885742611     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.09.004     Document Type: Article

References (50)

1. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:e21-e181.
2. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
3. Elkins J.S., Johnston S.C. Thirty-year projections for deaths from ischemic stroke in the United States. Stroke 2003, 34:2109-2112.
4. Johnston S.C., Fayad P.B., Gorelick P.B., et al. Prevalence and knowledge of transient ischemic attack among US adults. Neurology 2003, 60:1429-1434.
5. Johnston S.C., Gress D.R., Browner W.S., Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000, 284:2901-2906.
6. Hill M.D., Yiannakoulias N., Jeerakathil T., Tu J.V., Svenson L.W., Schopflocher D.P. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology 2004, 62:2015-2020.
7. Coull A.J., Lovett J.K., Rothwell P.M., Oxford Vascular S. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004, 328:326.
8. Lansberg M.G., O'Donnell M.J., Khatri P., et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl):e601S-e636S.
9. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
10. Lu G., Ades A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23:3105-3124.
11. Lu G., Ades A.E. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 2006, 101:447-459.
12. Woods B.S., Hawkins N., Scott D.A. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol 2010, 10:54.
13. van Valkenhoef G., Tervonen T., Zwinkels T., de Brock B, Hillege H. ADDIS: a decision support system for evidence-based medicine. Decis Support Syst 2013, 55:459-475.
14. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002, 21:2313-2324.
15. Caldwell D.M., Ades A.E., Higgins J.P. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331:897-900.
16. Salanti G., Higgins J.P., Ades A.E., Ioannidis J.P. Evaluation of networks of randomized trials. Stat Methods Med Res 2008, 17:279-301.
17. Salanti G., Kavvoura F.K., Ioannidis J.P. Exploring the geometry of treatment networks. Ann Intern Med 2008, 148:544-553.
18. Dias S., Welton N.J., Caldwell D.M., Ades A.E. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010, 29:932-944.
19. Gorelick P.B., Richardson D., Kelly M., et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003, 289:2947-2957.
20. Persantine Aspirin Trial in cerebral ischemia, part II: endpoint results. Stroke 1985, 16:406-415. The American-Canadian Co-Operative Study Group.
21. Bousser M.G., Eschwege E., Haguenau M., et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983, 14:5-14.
22. Fields W.S., Lemak N.A., Frankowski R.F., Hardy R.J. Controlled trial of aspirin in cerebral ischemia. Stroke 1977, 8:301-314.
23. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339. CAPRIE Steering Committee.
24. Culebras A., Rotta-Escalante R., Vila J., et al. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. Neurology 2004, 62:1073-1080.
25. Sorensen P.S., Pedersen H., Marquardsen J., et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks: a Danish cooperative study. Stroke 1983, 14:15-22.
26. Boysen G., Sorensen P.S., Juhler M., et al. Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke 1988, 19:1211-1215.
27. Group E.S., Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006, 367:1665-1673.
28. ESPS Group. Stroke 1990, 21:1122-1130. European Stroke Prevention Study.
29. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1-13.
30. Hankey G.J., Johnston S.C., Easton J.D., et al. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. Int J Stroke 2011, 6:3-9.
31. Huang Y., Cheng Y., Wu J., et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008, 7:494-499.
32. Diener H.C., Bogousslavsky J., Brass L.M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:331-337.
33. Matias-Guiu J., Ferro J.M., Alvarez-Sabin J., et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke 2003, 34:840-848.
34. Bousser M.G., Amarenco P., Chamorro A., et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011, 377:2013-2022.
35. Diener H.C., Sacco R., Yusuf S. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007, 23:368-380. Steering Committee, PROFESS Study Group.
36. Sacco R.L., Diener H.C., Yusuf S., et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008, 359:1238-1251.
37. Shinohara Y., Nishimaru K., Sawada T., et al. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial. Stroke 2008, 39:1827-1833.
38. Lancet 1991, 338:1345-1349. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group.
39. Shinohara Y., Katayama Y., Uchiyama S., et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010, 9:959-968.
40. Stroke 1987, 18:325-334. High-dose acetylsalicylic acid after cerebral infarction: aSwedish Cooperative Study.
41. Hass W.K., Easton J.D., Adams H.P., et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989, 321:501-507. Ticlopidine Aspirin Stroke Study Group.
42. Ito E., Takahashi A., Yamamoto H., et al. Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. Intern Med 2003, 42:793-799.
43. Farrell B., Godwin J., Richards S., Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991, 54:1044-1054.
44. Thijs V., Lemmens R., Fieuws S. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. Eur Heart J 2008, 29:1086-1092.
45. Verro P., Gorelick P.B., Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 2008, 39:1358-1363.
46. Geeganage C.M., Diener H.C., Algra A., et al. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke 2012, 43:1058-1066.
47. Maree A.O., Fitzgerald D.J. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007, 115:2196-2207.
48. Sweeny J.M., Gorog D.A., Fuster V. Antiplatelet drug "resistance," part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009, 6:273-282.
49. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809-1817.
50. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.